FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105496345> ?p ?o ?g. }

• W2105496345 endingPage "1909" @default.
• W2105496345 startingPage "1902" @default.
• W2105496345 abstract "Purpose The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is of interest. We conducted a single-arm phase II clinical trial of single-agent platinum for mTNBC with biomarker correlates. Patients and Methods Patients with mTNBC received first- or second-line cisplatin (75 mg/m 2 ) or carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. Coprimary end points were objective response rate (RR) and response prediction by p63/p73 gene expression. Secondary and exploratory end points included toxicity assessment, RR in cisplatin versus carboplatin, and RR in molecularly defined subgroups, including BRCA1/2 mutation carriers. Results Patients (N = 86; 69 as first-line therapy) received cisplatin (n = 43) or carboplatin (n = 43). RR was 25.6% (95% CI, 16.8% to 36%) and was numerically higher with cisplatin (32.6%) than with carboplatin (18.7%). RR was 54.5% in patients with germline BRCA1/2 mutations (n = 11). In patients without BRCA1/2 mutations (n = 66), exploratory analyses showed that a BRCA-like genomic instability signature (n = 32) discriminated responding and nonresponding tumors (mean homologous recombination deficiency–loss of heterozygosity/homologous recombination deficiency–large-scale state transitions [HRD-LOH/HRD-LST] scores were 12.68 and 5.11, respectively), whereas predefined analysis by p63/p73 expression status (n = 61), p53 and PIK3CA mutation status (n = 53), or PAM50 gene expression subtype (n = 55) did not. Five of the six long-term responders alive at a median of 4.5 years lacked germline BRCA1/2 mutations, and two of them had increased tumor HRD-LOH/HRD-LST scores. Conclusion Platinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations. A measure of tumor DNA repair function may identify patients without mutations who could benefit from platinum therapy agents. Prospective controlled confirmatory trials are warranted." @default.
• W2105496345 created "2016-06-24" @default.
• W2105496345 creator A5003417891 @default.
• W2105496345 creator A5005206482 @default.
• W2105496345 creator A5013104624 @default.
• W2105496345 creator A5019041034 @default.
• W2105496345 creator A5019992117 @default.
• W2105496345 creator A5027012132 @default.
• W2105496345 creator A5027040094 @default.
• W2105496345 creator A5027858713 @default.
• W2105496345 creator A5041593789 @default.
• W2105496345 creator A5052268581 @default.
• W2105496345 creator A5052735318 @default.
• W2105496345 creator A5056530735 @default.
• W2105496345 creator A5058502526 @default.
• W2105496345 creator A5060188343 @default.
• W2105496345 creator A5064496139 @default.
• W2105496345 creator A5067482697 @default.
• W2105496345 creator A5070245248 @default.
• W2105496345 creator A5073728088 @default.
• W2105496345 creator A5090188675 @default.
• W2105496345 date "2015-06-10" @default.
• W2105496345 modified "2023-10-12" @default.
• W2105496345 title "TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer" @default.
• W2105496345 cites W1993779806 @default.
• W2105496345 cites W2022289852 @default.
• W2105496345 cites W2051989799 @default.
• W2105496345 cites W2063382533 @default.
• W2105496345 cites W2065828547 @default.
• W2105496345 cites W2068868056 @default.
• W2105496345 cites W2074952360 @default.
• W2105496345 cites W2104024752 @default.
• W2105496345 cites W2105567212 @default.
• W2105496345 cites W2106292881 @default.
• W2105496345 cites W2113382133 @default.
• W2105496345 cites W2119480530 @default.
• W2105496345 cites W2125094267 @default.
• W2105496345 cites W2132619562 @default.
• W2105496345 cites W2134539328 @default.
• W2105496345 cites W2142486051 @default.
• W2105496345 cites W2144247813 @default.
• W2105496345 cites W2147629880 @default.
• W2105496345 cites W2149207987 @default.
• W2105496345 cites W2153769134 @default.
• W2105496345 cites W2161109798 @default.
• W2105496345 cites W2163814095 @default.
• W2105496345 cites W2171632978 @default.
• W2105496345 cites W2560367415 @default.
• W2105496345 doi "https://doi.org/10.1200/jco.2014.57.6660" @default.
• W2105496345 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4451173" @default.
• W2105496345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25847936" @default.
• W2105496345 hasPublicationYear "2015" @default.
• W2105496345 type Work @default.
• W2105496345 sameAs 2105496345 @default.
• W2105496345 citedByCount "334" @default.
• W2105496345 countsByYear W21054963452015 @default.
• W2105496345 countsByYear W21054963452016 @default.
• W2105496345 countsByYear W21054963452017 @default.
• W2105496345 countsByYear W21054963452018 @default.
• W2105496345 countsByYear W21054963452019 @default.
• W2105496345 countsByYear W21054963452020 @default.
• W2105496345 countsByYear W21054963452021 @default.
• W2105496345 countsByYear W21054963452022 @default.
• W2105496345 countsByYear W21054963452023 @default.
• W2105496345 crossrefType "journal-article" @default.
• W2105496345 hasAuthorship W2105496345A5003417891 @default.
• W2105496345 hasAuthorship W2105496345A5005206482 @default.
• W2105496345 hasAuthorship W2105496345A5013104624 @default.
• W2105496345 hasAuthorship W2105496345A5019041034 @default.
• W2105496345 hasAuthorship W2105496345A5019992117 @default.
• W2105496345 hasAuthorship W2105496345A5027012132 @default.
• W2105496345 hasAuthorship W2105496345A5027040094 @default.
• W2105496345 hasAuthorship W2105496345A5027858713 @default.
• W2105496345 hasAuthorship W2105496345A5041593789 @default.
• W2105496345 hasAuthorship W2105496345A5052268581 @default.
• W2105496345 hasAuthorship W2105496345A5052735318 @default.
• W2105496345 hasAuthorship W2105496345A5056530735 @default.
• W2105496345 hasAuthorship W2105496345A5058502526 @default.
• W2105496345 hasAuthorship W2105496345A5060188343 @default.
• W2105496345 hasAuthorship W2105496345A5064496139 @default.
• W2105496345 hasAuthorship W2105496345A5067482697 @default.
• W2105496345 hasAuthorship W2105496345A5070245248 @default.
• W2105496345 hasAuthorship W2105496345A5073728088 @default.
• W2105496345 hasAuthorship W2105496345A5090188675 @default.
• W2105496345 hasBestOaLocation W21054963451 @default.
• W2105496345 hasConcept C121608353 @default.
• W2105496345 hasConcept C126322002 @default.
• W2105496345 hasConcept C143998085 @default.
• W2105496345 hasConcept C2776694085 @default.
• W2105496345 hasConcept C2778239845 @default.
• W2105496345 hasConcept C2780110267 @default.
• W2105496345 hasConcept C2781197716 @default.
• W2105496345 hasConcept C2781451048 @default.
• W2105496345 hasConcept C530470458 @default.
• W2105496345 hasConcept C54355233 @default.
• W2105496345 hasConcept C71924100 @default.
• W2105496345 hasConcept C86803240 @default.
• W2105496345 hasConceptScore W2105496345C121608353 @default.

• next